StocksMedium•16 November 2026•
1 min read
MiniMed Receives FDA Clearance for First 7-Day Tubeless Insulin Pump
Key Facts
1MiniMed received FDA clearance for MiniMed Fit, the first tubeless insulin pump offering up to seven days of wear and a 300-unit capacity.
MiniMed received FDA clearance for MiniMed Fit, the first tubeless insulin pump offering up to seven days of wear and a 300-unit capacity. PR Newswire reported that the device utilizes SmartGuard automation technology to eliminate the need for charging or cartridge changes for a full week.
MMED closed at $17.99 on November 13, 2026, with the stock reaching a day high of $18.15 and a low of $17.65 during that session. This regulatory milestone provides a new tubeless option for diabetes management, aimed at reducing the frequency of device changes for patients.